Merkelig at den plutselig går så mye, trodde ikke de siste meldingene ville trigge nye kjøpere. Vurderer å gå inn igjen her selv, synes teknologien virker som en vinner på sikt.
1 Like
Fra 5 til 85 kroner da capo hadde gjort seg
2 Likes
Men joa
Joda, men samtidig verdien burde kunne bli en del ganger større enn den var i 2014 hvis det begynner å løsne for selskapet
1 Like
Ligger vel an til en ny runde med innhenting av ny kapital?
1 Like
Jo, men nå vil de ikke kjøre store emisjoner som sist, men en konvertibel løsning. Det er så klart heller ikke uten problemer så det kan nok legge en demper på kursen såfremt det ikke presenteres noen fremdrift.
1 Like
Får se om jeg lar meg lokke utpå igjen. Fremdriften virker å gå svært sakte, til tross for gode resultater på utførte operasjoner og innvilgede patenter.
1 Like
Det attraktive her er at man kan fort få en episk hockey stick, ved at flere og flere klinikker får teknologi og opplæring, og så plutselig kan frekvensen på hver klinikk femdobles.
Veldig likt Photocure og utplasserte skop.
Men det tar tid, og det koster penger. Inntektene til Episurf er fantastisk lave enda.
2 Likes
Nå begynner det i hvert fall å komme inn femårs-data sakte men sikkert, noe vi vet er viktig for kirurgene.
2 Likes
Episurf Medical to present at Börsveckans Småbolagsdag, held in Stockholm, September 5
Episurf Medical will present at Börsveckans Småbolagsdag, a small-cap investor conference, held in Stockholm on September 5 (Operaterassen, Karl XII:s torg, Stockholm). The event is arranged by Financial Hearings and the company will be represented by CEO Pål Ryfors.
The presentation will be available on the company’s website after the presentation.
For full program and registration, see link. (https://financialhearings.com/event/9634)
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Ekstern link: http://news.cision.com/episurf/r/episurf-medical-to-present-at-borsveckans-smabolagsdag–held-in-stockholm–september-5,c2591493
Ekstern link: http://mb.cision.com/Main/14691/2591493/890845.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180814.Cision.20180813:BIT:7693:0
New Australian patent approval for Episurf Medical
The Australian patent office IP Australia has announced that Episurf Medical (NASDAQ: EPIS B) has obtained another granted patent in Australia. The patent, entitled “Design method of a rig”, is within the area of individualised surgical instruments with a focus on the drill guide for the Episealer® Femoral Twin implant.
“I’m happy to see how the Episealer® Femoral Twin technology is getting backed up by a strong patent coverage globally”, comments Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 15 August 2018.
Ekstern link: http://news.cision.com/episurf/r/new-australian-patent-approval-for-episurf-medical,c2592457
Ekstern link: http://mb.cision.com/Main/14691/2592457/891486.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180815.Cision.20180814:BIT:8657:0
Da er vi over sma200 igjen
Episurf Medical will exhibit at the 2018 SOF Congress, held in Karlstad, Sweden, on August 27-31
Episurf Medical (NASDAQ: EPIS B) will exhibit at the 2018 SOF Congress (Swedish Orthopaedic Association), held in Karlstad, Sweden (Karlstad CCC), on August 27-31. As previously communicated, Ass Prof Karl Eriksson (Stockholm South General Hospital), will present clinical results from patients treated with the Episealer® knee implant.
For full program, see http://www.ortopediveckan.se/. For an overview of the industry conferences attended by Episurf Medical, see link. (www.episurf.com/healthcare-professionals/conferences).
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Ekstern link: http://news.cision.com/episurf/r/episurf-medical-will-exhibit-at-the-2018-sof-congress–held-in-karlstad–sweden–on-august-27-31,c2593980
Ekstern link: http://mb.cision.com/Main/14691/2593980/892575.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180816.Cision.20180816:BIT:0180:0
First Canadian patent approval for Episurf Medical
Episurf Medical (NASDAQ: EPIS B) has received its first Notice of Allowance from the The Canadian Intellectual Property Office (CIPO).
The patent, entitled “Surgical kit for cartilage repair comprising implant and a set of tools”, has a focus on the company’s individualised Episealer® Femoral Twin joint implant and its design.
“The first approval in a for us new country is an important step. We are looking forward to future activities in North America”, comments Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.55 CEST on 29 August 2018.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
Ekstern link: http://news.cision.com/episurf/r/first-canadian-patent-approval-for-episurf-medical,c2603083
Ekstern link: http://mb.cision.com/Main/14691/2603083/899137.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180829.Cision.20180829:BIT:9383:0
New Australian patent approval for Episurf Medical
The Australian patent office IP Australia has issued a Notice of acceptance for another patent for Episurf Medical (NASDAQ: EPIS B) in Australia. The patent, entitled “Method and node for manufacturing a surgical kit for cartilage repair” covers Episurf Medical’s medical image segmentation process used for joint structure visualisation.
“This patent covers important details of the segmentation process Episurf Medical uses for 3D visualisation of joints, which is a central part of our technology platform”, comments Katarina Flodström, CRO & Head of IP, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.35 CEST on 29 August 2018.
Ekstern link: http://news.cision.com/episurf/r/new-australian-patent-approval-for-episurf-medical,c2603686
Ekstern link: http://mb.cision.com/Main/14691/2603686/899468.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180829.Cision.20180829:BIT:9986:0
Change in number of shares and votes in Episurf Medical
Episurf Medical AB (NASDAQ: EPIS B) has performed conversion of convertible bonds issued under the financing agreement published February 23, 2018. The number of convertibles converted in August was 28. The number of convertibles remaining during the first tranche for future conversion is 92. Through the conversion, the number of shares and votes increased by 373,333. The terms of the convertibles are published on Episurf Medical AB’s website.
The total number of shares amounts to 31,126,909, of which 5,257,078 are A shares and 25,869,831 are B shares. The total number of votes after the conversions amounts to 41,641,065.
For more information, please contact:
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com)
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CEST on 31 August 2018.
Ekstern link: http://news.cision.com/episurf/r/change-in-number-of-shares-and-votes-in-episurf-medical,c2601561
Ekstern link: http://mb.cision.com/Main/14691/2601561/898012.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180831.Cision.20180827:BIT:7861:0
Correction of press release regarding change in number of shares and votes in Episurf Medical
In the press release that was sent out at 11.00, it was incorrectly stated that the information was made public pursuant to the EU Market Abuse Regulation. The corrected press release in its entirety follows below.
Episurf Medical AB (NASDAQ: EPIS B) has performed conversion of convertible bonds issued under the financing agreement published February 23, 2018. The number of convertibles converted in August was 28. The number of convertibles remaining during the first tranche for future conversion is 92. Through the conversion, the number of shares and votes increased by 373,333. The terms of the convertibles are published on Episurf Medical AB’s website.
The total number of shares amounts to 31,126,909, of which 5,257,078 are A shares and 25,869,831 are B shares. The total number of votes after the conversions amounts to 41,641,065.
For more information, please contact:
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com)
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 15:00 CEST on August 31, 2018.
Ekstern link: http://news.cision.com/episurf/r/correction-of-press-release-regarding-change-in-number-of-shares-and-votes-in-episurf-medical,c2605836
Ekstern link: http://mb.cision.com/Main/14691/2605836/900974.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180831.Cision.20180831:BIT:2236:0
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre 
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @Savepig (9 likes)
- @holmes (8 likes)
- @Aksjesnila (8 likes)
Resten av topp 10:
-
@Fenriz (2 likes)
-
@nofun (1 likes)
-
@Montebello (1 likes)
Gratulerer!
Promising clinical results from use of Episealer® accepted for presentation at annual meeting of the Australian Knee Society
Episurf Medical (NASDAQ: EPIS B) today announces that the scientific abstract “Clinical results of an individualized mini-metal implant for focal cartilage lesions in the knee” by Ass. Prof. Karl Eriksson et al. has been accepted for presentation at the annual congress of the Australian Knee Society (AKS). The congress will take place in Broome, Australia on October 11-13, 2018. The abstract focuses on interim results from a European multicenter study with the Episealer® knee implant. The results will be presented by Ass. Prof. Karl Eriksson from Stockholm South General Hospital, Sweden.
“We are happy that the clinical results from use of the Episealer implant will be presented at this meeting. The results show high patient reported scores and a low early revision rate and this is exactly what we want to achieve. Our customers attest to the treatment gap and all proofs of successful treatment of this patient group are highly interesting. We are currently reviewing the regulatory pathway for a market entrance in Australia and it is definitely a market for us on mid- to long-term.” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Ekstern link: http://news.cision.com/episurf/r/promising-clinical-results-from-use-of-episealer–accepted-for-presentation-at-annual-meeting-of-the,c2620111
Ekstern link: http://mb.cision.com/Main/14691/2620111/910597.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180918.Cision.20180917:BIT:6611:0
1 Like
Lurer på hvem dette kan være, “en gruppe nordiske private investorer”
EPISURF MEDICAL
PRIVATINVESTERARE HAR KÖPT KAUPTHINGS INNEHAV (Direkt)
2018-09-18 08:48
STOCKHOLM (Direkt) En grupp nordiska privata investerare har köpt Kaupthings aktiepost i Episurf Medical om drygt 500.000 aktier, motsvarande 3,1 procent av kapitalet.Försäljningen har skett i linje med den kontrollerade likvidationen av Kaupthings tillgångsportfölj, heter det i ett pressmeddelande.
Börsredaktionen +46 8 5191 79 00 http://twitter.com/direktse
Nyhetsbyrån Direkt
1 Like